Results 141 to 150 of about 20,494 (185)

An antibody-PROTAC conjugate targets BRD4/c-Myc/PD-L1 to enhance immunotherapy efficacy in triple-negative breast cancer. [PDF]

Cell Rep Med
Gu Y, Li C, Zhao Y, Xu T, Zhu Y, Wang D, Wang X, Chen J, Li J, Guan X.   +9 more
europepmc   +1 more source

Eyes Toward the Clinic: Selective Inhibition and Degradation Approaches to Bromodomain-Containing Proteins. [PDF]

Chembiochem
Scholtz CR, Pomerantz WCK.
europepmc   +1 more source

BET inhibition curbs macrophage inflammation, lipid accumulation, and atherogenesis by disrupting the YAP/TAZ-BRD4 axis. [PDF]

J Leukoc Biol
Veerasubramanian PK, Meli VS, Atcha H, Wang W, Downing TL, Liu WF.   +5 more
europepmc   +1 more source

Identification of Clofibric Acid as a Synoviolin (SYVN1) Ligand for Proteolysis-Targeting Chimera (PROTAC) Development. [PDF]

ACS Med Chem Lett
Warren J, Munakala A, Zientek KD, Kim K, Wilmarth PA, Reddy AP, Li BX, Xiao X.   +7 more
europepmc   +1 more source

pH sensing and inflammation: linking acidic microenvironments to immune reprogramming. [PDF]

Front Immunol
Zhang M, Tian J, Sun W.
europepmc   +1 more source

PROTAC-based nanoassemblies targeting BRD4 for potentiate FLASH radiosensitization therapy. [PDF]

Mater Today Bio
Xu R, Han X, Sun Y, Ma C, Liao S, Tang R, Pu Y, Zheng X, Zhang J, Yang W, Li X, Yang Z.   +11 more
europepmc   +1 more source

Chromatin dynamics and cellular energy homeostasis. [PDF]

J Biochem
Suganuma T, Workman JL.
europepmc   +1 more source

Laryngeal NUT Carcinoma With BRD4::NUTM1 Fusion: A 4-Year Clinical Course Highlighting the Limitations of Current Multimodal Therapy. [PDF]

Cancer Rep (Hoboken)
Kanno M, Sasaki C, Kato E, Terada H, Hanai N, Sasaki E, Fukushima M, Masuishi T, Takanari K, Fukada Y, Miyazaki Y, Sonoda Y, Kato Y, Morikawa T, Takabayashi T, Fujieda S.   +15 more
europepmc   +1 more source

BRD4 PROTAC degrader enhances fulvestrant sensitivity in ER+ breast cancer via super-enhancer associated GREB1. [PDF]

Front Oncol
Zhang X, Zheng P, Liu Z, Zhang Q, Duan W, Zhang T, Liu X.   +6 more
europepmc   +1 more source

ISL@mTOMV nanoparticles: a promising approach for VM-targeted therapy in breast cancer. [PDF]

J Nanobiotechnology
Fu C, Li Z, Tang B, Fan Z, Luo Y, Yi X, Shu B, Liu Z, Jiang B, Li Y.   +9 more
europepmc   +1 more source